Coalition for Epidemic Preparedness Innovations (CEPI)

The challenges

There is a global gap in vaccine research and development for infectious diseases likely to cause outbreaks in developing countries (where market incentives alone will not drive product development).

Historically, vaccine development has been a long, risky, and costly endeavour. Planning for emerging infectious diseases is especially challenging: the market potential for vaccines against these diseases is limited and testing such vaccines is difficult.

We need a better system to speed up the development of vaccines against emerging infectious diseases.

How will we address the challenge?

By funding the Coalition for Epidemic Preparedness Innovations (CEPI), a non-profit organisation that seeks to develop vaccines against emerging infectious diseases, particularly those that affect people in lower and middle-income countries. CEPI also develops new vaccine technology that can enable fast manufacture of new vaccines for people during outbreaks.


Global, a particular focus on key countries in the Indo-Pacific Region.


The Coalition for Epidemic Preparedness Innovations (CEPI) - $4.5 million 2019-2022.

What will success look like?

Vaccines against known threats such as Nipah Virus Disease and Lassa Fever will have been accelerated and stockpiles will have been established at strategic locations before epidemics - “just in case”.

New technologies will have been established to speed up the development and manufacture of vaccines against previously unknown infectious diseases - “just in time”.

Regulatory systems will have been strengthened to enable safe, speedy delivery of new vaccines.